Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Inotiv, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
20.4
24.2
26.3
43.6
60.5
89.6
548
572
491
513
Cost of revenue
16
16.5
18.2
29.6
42.2
59.4
Gross profit
4.43
7.7
8.12
14
18.2
30.2
Research and development
0.5
0.47
0.6
0.63
0.62
0.41
General and administrative
4.58
4.9
5.97
10.6
17
23.2
82.4
105
77
71.1
Operating expenses
7.47
6.42
8.1
14.2
21.3
35.8
Operating income
-3.04
1.28
0.01
-0.15
-3.06
-5.62
-263
-81.5
-86.4
-30.9
Interest expense
0.4
0.38
0.27
0.64
1.49
1.68
29.7
43
46.9
56.6
Other non-operating income
0.01
0.01
0.01
0.01
0.02
13.4
-59.3
0.24
2.53
-0.27
Pre-tax income
-3.24
0.91
-0.25
-0.79
-4.54
6.12
-352
-124
-131
-87.8
Income tax
-0.01
0.02
-0.06
0
0.15
-4.78
-15.2
-19.3
-21.9
-19.1
Net income to minority interests
0
-0.24
0.24
-0.44
0
Net income
-3.23
0.88
-0.19
-0.79
-4.69
10.9
-337
-105
-108
-68.6
EBITDA
-1.48
2.96
1.89
2.56
1.01
0.65
-214
-26.7
-29.3
25
EPS, basic
-0.40
0.11
-0.02
-0.08
-0.43
0.83
-13.84
-4.10
-4.19
-2.11
EPS, diluted
-0.40
0.10
-0.02
-0.08
-0.43
0.19
-13.84
-4.10
-4.19
-2.11
Shares, basic (weighted)
8.11
8.18
8.77
10.4
10.9
13.2
24.4
25.6
25.9
32.5
Shares, diluted (weighted)
8.11
8.73
8.77
10.4
10.9
13.9
24.4
25.6
25.9
32.5
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.39
0.43
0.61
0.61
1.41
139
18.5
35.5
21.4
21.7
Receivables
1.65
2.53
4.13
7.18
8.68
22.8
88.9
Inventory
1.45
0.91
1.18
1.1
0.7
0.6
71.4
56.1
18.2
45.7
Other current assets
0.8
0.81
0.97
1.2
2.37
1.2
8.25
6.82
4.86
6.77
Total current assets
4.88
5.31
8.06
12.4
15.3
189
233
214
163
195
Property, plant and equipment
16.1
15
16.6
22.8
28.7
48
186
191
188
181
Lease right-of-use assets
0
4
8.36
32.5
38.9
49.2
46.4
Goodwill
0.04
0.04
3.07
3.62
4.37
51.9
158
94.3
94.3
94.3
Intangible assets
0
3.33
2.88
4.26
24.2
346
308
274
240
Other non-current assets
0.03
0.02
0.03
0.07
0.08
0.34
7.52
10.1
11.8
15
Total assets
21.1
20.4
31.3
42
61.6
322
963
857
781
771
Accounts payable
2.97
2.05
3.19
4.94
3.2
6.16
28.7
32.6
33.5
48.5
Accrued liabilities
1.09
1.2
1.57
2.66
2.69
8.97
35.8
25.8
28.2
44.7
Deferred revenue
4.93
6.73
11.4
26.6
29.4
18.9
17.1
18.4
Short-term debt
3.66
0.22
0.91
1.11
5.99
9.66
7.98
7.95
3.54
402
Total current liabilities
13.5
7.72
11.8
17.5
31.6
55.1
164
132
119
557
Long-term debt
0
4.16
8.55
13.8
18.8
154
331
370
390
0
Lease liabilities
0
3.34
6.55
24.9
29.6
40
44.3
Other non-current liabilities
0.51
6.48
6.37
35
28.4
Total liabilities
13.7
12
20.4
31.3
54
217
603
588
611
635
Total debt
3.67
4.45
9.61
15.1
25.1
170
351
378
393
402
Paid-in capital
21.2
21.4
24.6
25.2
26.8
112
708
716
725
756
Retained earnings
-16.9
-16
-16.2
-17.1
-21.9
-11
-348
-453
-562
-631
Other comprehensive income
-0.04
0
0
-5.5
0.33
1.41
2.23
Shareholders' equity
7.46
8.47
10.7
10.7
7.6
105
360
269
171
136
Minority interests
0
-0.61
-0.66
0
Total equity
7.46
8.47
10.7
10.7
7.6
105
360
268
171
136
Total liabilities and equity
21.1
20.4
31.3
42
61.6
322
963
857
781
771
Shares outstanding
8.11
8.24
10.2
10.5
11
15.9
25.6
25.8
26
34.4
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-3.23
0.29
-0.19
-0.79
-4.69
10.9
-337
-105
-109
-68.6
Depreciation and amortization
1.56
1.68
1.88
2.72
4.07
6.27
49.3
54.7
57.1
55.9
Stock-based compensation
0.05
0.02
0.13
0.28
0.54
1.79
24.2
7.84
6.74
6.03
Deferred income tax
0
-17.8
-25.8
-23.3
-21.6
Change in receivables
1.64
-0.94
-0.59
-3.27
-0.62
-12
-23.8
9.55
14.2
-3.83
Change in inventory
0.01
0.54
-0.27
0.09
0.4
0.1
-35.2
14
38.2
-27.6
Change in payables
1.12
-0.91
0.98
1.02
-2.05
2.62
-8.04
5.96
0.61
12.3
Cash from operations
1.06
1.24
3.49
1.78
1.29
10.7
-5.22
27.9
-6.81
-10.5
Capital expenditures
-1.26
-0.35
-1.32
-6.88
-6.2
-12.5
-36.3
-27.5
-22.3
-16.6
Acquisitions
0
-6.76
-1.27
-3.93
-41.6
-298
0
Cash from investing
-1.26
-0.34
-8.07
-8.15
-10.1
-54.1
-334
-28.8
-16.8
-12.9
Debt issued
0
4.5
5.5
1.27
8.78
18.3
0
35
0
0
Debt repaid
-0.79
-3.72
-0.33
-0.91
-1.85
-4.15
-36.8
0
Stock issued
0
0.07
0
0.01
0.03
49
0
0
0
27.5
Cash from financing
0.14
-0.85
4.93
6.21
9.64
199
203
15.9
9.68
23.7
Exchange rate effect
0
-2.16
1.51
-0.1
-0.05
Net change in cash
-0.05
0.05
0.34
-0.17
0.8
156
-138
16.5
-14.1
0.31
Free cash flow
-0.2
0.89
2.17
-5.1
-4.91
-1.73
-41.5
0.38
-29.1
-27.1
Interest paid
0.31
0.23
0.23
0.57
1.04
1.27
17.1
35.5
36.1
38.8
Income taxes paid
0
0.02
0.01
0.01
0.01
0.01
0.48
7.15
1.84
0.75
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.01 on July 24, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-9.5%
Operating income / revenue.
EBITDA margin
1.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-20.8%
Pre-tax income / revenue.
Net margin
-17.1%
Net income / revenue.
FCF margin
-2.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
0.1%
Cash from operations / revenue.
Return on equity (ROE)
-112.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-12.4%
Net income / average total assets.
Return on invested capital (ROIC)
-8.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue
1.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.8%
Capital expenditures / revenue.
D&A / revenue
11.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
4.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-2.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
53.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA CAGR, 5y
90.0%
Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-20.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-27.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
78.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-1.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-7.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
65.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
25.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
10.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
24.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.27x
Current assets / current liabilities.
Quick ratio
0.03x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.03x
(Cash + short-term investments) / current liabilities.
Debt / equity
5.32x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
58.4%
Total debt / total assets.
Liabilities / assets
89.0%
Total liabilities / total assets.
Net debt
$395.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
51.3x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$2.51
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$14.64
Revenue / diluted weighted shares.
FCF per share
-$0.39
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.01
Cash from operations / diluted weighted shares.
Book value per share
$2.21
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.00x
Market cap / revenue.
P/B
0.00x
Market cap / shareholders' equity. Only when equity is positive.
P/OCF
1.08x
Market cap / cash from operations, when positive.
EV/Sales
0.78x
Enterprise value / revenue.
EV/EBITDA
51.4x
Enterprise value / EBITDA, when both are positive.
FCF yield
-3,547.0%
Free cash flow / market cap.
Earnings yield
-22,663.0%
Net income / market cap (the inverse of P/E).
What was Inotiv, Inc.'s revenue in fiscal 2025?
Inotiv, Inc. reported revenue of $513.0M for fiscal 2025, 4.5% higher than the year before.
Was Inotiv, Inc. profitable in fiscal 2025?
No. It reported a net loss of $68.6M.
How much free cash flow did Inotiv, Inc. generate in fiscal 2025?
Cash from operations of $10.5M minus capital expenditures of $16.6M left free cash flow of -$27.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.